Blackstone Life Sciences (BX) announced a research and development funding agreement to advance the clinical development of bleximenib, an investigational oral menin inhibitor, for acute myeloid leukemia. Johnson & Johnson (JNJ) and funds managed by BXLS will jointly finance a portion of the ongoing and future clinical trials of bleximenib in AML. This is the first time that BXLS and Johnson & Johnson have entered into a co-funding agreement.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BX:
- Blackstone Life Sciences announces a AML co-funding agreement with J&J
- FERC authorizes TXNM Energy acquisition by Blackstone Infrastructure
- Blackstone price target lowered to $137 from $171 at UBS
- Volkswagen attracts bids from private equity funds for Everllence, FT says
- Blackstone announces agreement to acquire Champions Group